Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
October 13, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris To Present at the APAAACI 2023 International Conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
October 04, 2023 07:34 ET | Source: Pharvaris N.V.

Pharvaris To Present at the CIIC Fall 2023 Conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
September 19, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
September 06, 2023 06:51 ET | Source: Pharvaris N.V.

Pharvaris To Present at the 18th German Allergy Congress

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
September 06, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
August 23, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
August 07, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3...
July 21, 2023 10:20 ET | Source: Pharvaris N.V.

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
June 26, 2023 06:50 ET | Source: Pharvaris N.V.

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...